Trial Profile
A Cancer Research UK Phase I Trial of AST-VAC2 (Allogeneic Dendritic Cell Vaccine) Administered Weekly Via Intradermal Injection in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Aug 2023
Price :
$35
*
At a glance
- Drugs VAC 2 (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; First in man
- 24 Jul 2023 Results presented in a Lineage Cell Therapeutics Media Release.
- 24 Jul 2023 According to a Lineage Cell Therapeutics media release, Lineage, Cancer Research UK, and the participating investigators intend to present data from this trial at future medical and scientific conferences and submit publications to relevant journals for peer review.
- 24 Jul 2023 Results published in the Lineage Cell Therapeutics Media Release